BenzingaAugust 31, 2026 at 4:22 AM NYLast Month
Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $136
Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $142 to $136.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
